ATE481495T1 - Adenovirusvektor - Google Patents

Adenovirusvektor

Info

Publication number
ATE481495T1
ATE481495T1 AT03730847T AT03730847T ATE481495T1 AT E481495 T1 ATE481495 T1 AT E481495T1 AT 03730847 T AT03730847 T AT 03730847T AT 03730847 T AT03730847 T AT 03730847T AT E481495 T1 ATE481495 T1 AT E481495T1
Authority
AT
Austria
Prior art keywords
adenovirus vector
cells
stem cells
cell lines
specific cell
Prior art date
Application number
AT03730847T
Other languages
English (en)
Inventor
Hiroyuki Mizuguchi
Takao Hayakawa
Fuminori Sakurai
Original Assignee
Fuso Pharmaceutical Ind
Hiroyuki Mizuguchi
Takao Hayakawa
Fuminori Sakurai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29727559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481495(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fuso Pharmaceutical Ind, Hiroyuki Mizuguchi, Takao Hayakawa, Fuminori Sakurai filed Critical Fuso Pharmaceutical Ind
Application granted granted Critical
Publication of ATE481495T1 publication Critical patent/ATE481495T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03730847T 2002-06-05 2003-06-05 Adenovirusvektor ATE481495T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002164015A JP4237449B2 (ja) 2002-06-05 2002-06-05 アデノウィルスベクター
PCT/JP2003/007146 WO2003104469A1 (ja) 2002-06-05 2003-06-05 アデノウイルスベクター

Publications (1)

Publication Number Publication Date
ATE481495T1 true ATE481495T1 (de) 2010-10-15

Family

ID=29727559

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03730847T ATE481495T1 (de) 2002-06-05 2003-06-05 Adenovirusvektor

Country Status (8)

Country Link
US (1) US9540658B2 (de)
EP (1) EP1533381B1 (de)
JP (1) JP4237449B2 (de)
AT (1) ATE481495T1 (de)
AU (1) AU2003242160B2 (de)
CA (1) CA2488058C (de)
DE (1) DE60334222D1 (de)
WO (1) WO2003104469A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010149A2 (en) * 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
WO2013032918A1 (en) 2011-08-26 2013-03-07 Yecuris Corporation Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof
WO2020166727A1 (ja) * 2019-02-12 2020-08-20 国立大学法人大阪大学 ヒト３５型アデノウイルスを基板とした腫瘍溶解性ウイルス

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880102A (en) * 1995-01-17 1999-03-09 Duke University Adenoviral vector system
US5849561A (en) 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
DK1818408T3 (da) * 1999-05-17 2011-10-17 Crucell Holland Bv Rekombinant adenovirus af serotypen Ad11
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AU5161600A (en) * 1999-05-27 2000-12-18 Genzyme Corporation Methods for induction of tolerance to adenoviral vectors and transgene products
US20010033833A1 (en) * 1999-12-08 2001-10-25 Schraa Edwin Oscar Method of administering adenovirus
WO2001090392A1 (en) * 2000-05-26 2001-11-29 Sumitomo Pharmaceuticals Company, Limited Novel recombinant adenovirus vector with relieved side effects
WO2002053759A1 (en) * 2001-01-04 2002-07-11 Wadell Goeran Viral vector for gene therapy
CA2495546A1 (en) * 2002-08-22 2004-03-04 Merck & Co., Inc. Methods for propagating adenovirus and virus produced thereby

Also Published As

Publication number Publication date
AU2003242160B2 (en) 2007-08-02
CA2488058C (en) 2011-11-22
DE60334222D1 (en) 2010-10-28
EP1533381A1 (de) 2005-05-25
EP1533381B1 (de) 2010-09-15
WO2003104469A1 (ja) 2003-12-18
JP4237449B2 (ja) 2009-03-11
CA2488058A1 (en) 2003-12-18
AU2003242160A1 (en) 2003-12-22
US20050176129A1 (en) 2005-08-11
JP2004008047A (ja) 2004-01-15
US9540658B2 (en) 2017-01-10
EP1533381A4 (de) 2005-11-16

Similar Documents

Publication Publication Date Title
CA2338541A1 (en) Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy
JP2020063263A5 (de)
NO990025L (no) Hamster-EF-1<alfa> transkripsjonsregulatorisk DNA
CA2193094A1 (en) The cytoplasmic inhibition of gene expression
WO2001051006A3 (en) Cardiac-cell specific enhancer elements and uses thereof
DE602006019422D1 (de) Verbesserte expressionselemente
NO20035732L (no) Diagnostiske analyser for parvovirus B19
NL300046I2 (nl) Eiwit met uraat oxidase activiteit, recombinant gen dat hiervoor codeert, expressievector, micro-organismen en getransformeerde cellen.
BRPI0303570B8 (pt) "construção de hgf, microrganismo transgênico, vetor e composição farmacêutico"
DE60142519D1 (de) Dna-expressionsvektoren
WO2001030992A3 (en) α1-3 GALACTOSYLTRANSFERASE GENE AND PROMOTER
MA28779B1 (fr) Variants d'aprotinine ameliores
DE69941013D1 (de) Hocheffiziente säugetier expressionsvektoren die eht-translatierte region oberhalb des startcodons enthalten als transkriptionsregulationsstätte für inhärente gene
ATE481495T1 (de) Adenovirusvektor
WO2005010149A3 (en) Subgroup b adenoviral vectors for treating disease
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
DE60031369D1 (de) Replikation -defektive baculoviren expressionssystem
DE69940267D1 (de) Wirtszellen, die rekombinantes humanes erythropoietin exprimieren
UA126792C2 (uk) Регуляторний елемент рослин і його застосування
DE69737388D1 (de) Immortalisierte geflügelzellinien
EA200800098A1 (ru) Экспрессионный вектор и способ продуцирования высоких уровней белков
ATE317020T1 (de) Neues regulationssystem zur kontrolle der expression eines transgens
RU2009104533A (ru) Способы обнаружения болезни альцгеймера
HUP9904201A1 (hu) Génterápiában használható, egy exogén nukleinsavat genomjában beépítve tartalmazó rekombináns vírus és egy nem virális és nem plazmid transzfektáló szer kombinációját tartalmazó transzfektáló készítmény
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties